November 30, 2023 12:00 PM EST
Manufacturing

2024 VC fore­cast: Clin­i­cal-stage CD­MOs like­ly to have uptick in de­mand but spe­cial­iza­tion crit­i­cal

Anna Brown

News Reporter

Clin­i­cal-stage CD­MOs should ex­pect a rise in de­mand in 2024 as fund­ing for ear­ly-stage bio­phar­ma sta­bi­lizes and biotechs may shed their in-house man­u­fac­tur­ing to save …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times